Picture of G1 Therapeutics logo

GTHX — G1 Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapHigh Flyer

G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 20 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -53 cents.  The mean expectation of five analysts for the
quarter was for a loss of 21 cents per share. Wall Street
expected results to range from -22 cents to -20 cents per share.
    * Revenue rose 11.8% to $14.48 million from a year ago;
analysts
expected $15.26 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 20 cents​.
    * The company reported a quarterly loss of $10.22 million.
    * G1 Therapeutics Inc shares had fallen by 12.7% this
quarter and
gained 23.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 27.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for G1 Therapeutics
Inc is $8.50 
This summary was machine generated from LSEG data May 1 at 01:32
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.21          -0.20          Beat
 Dec. 31 2023      -0.28          -0.21          Beat
 Sep. 30 2023      -0.33          -0.35          Missed
 Jun. 30 2023      -0.22          0.14           Beat

Recent news on G1 Therapeutics

See all news